PerkinElmer acquires ViaCell

By Lisa Kerner

Charlotte, N.C., Nov. 15 - PerkinElmer, Inc. said Thursday it expanded its reach in the neonatal, prenatal and maternal health markets with the completed acquisition of ViaCell, Inc.

As previously reported, PerkinElmer acquired 37.9 million shares, or more than 90%, of ViaCell's common stock in its $7.25-per-share tender offer ended Nov. 8.

"PerkinElmer is committed to protecting the health of mothers and babies from pregnancy through birth and beyond," president and chief operating officer Robert F. Friel said in a company news release.

"We will continue to look for opportunities to build our product portfolio and provide the most comprehensive and accurate assessment of newborn and maternal health to families and their healthcare providers," Friel added.

PerkinElmer is a Waltham, Mass.-based health sciences and photonics company. ViaCell is a biotechnology company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.